Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

• Published in: Clinical cancer research 2021-07, Vol.27 (14), p.3834-3844
• Main Authors: Takebe, Naoko, Naqash, Abdul Rafeh, O'Sullivan Coyne, Geraldine, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B, Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J, Parchment, Ralph E, Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H, Chen, Alice P
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - analysis; Cell Cycle Proteins - antagonists & inhibitors; Drug Administration Schedule; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - therapeutic use; Female; Humans; Male; Middle Aged; Neoplasms - chemistry; Neoplasms - drug therapy; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidinones - adverse effects; Pyrimidinones - therapeutic use; Treatment Outcome
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.CCR-21-0329

The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report results for once-daily adavosertib. A 3 + 3 dose-escalation design was used, with adavosertib given once daily on days 1 to 5 and 8 to 12 in 21-day cycles. Molecular biomarkers of Wee1 activity, including tyrosine 15-phosphorylated Cdk1/2 (pY15-Cdk), were assessed in paired tumor biopsies. Whole-exome sequencing and RNA sequencing of remaining tumor tissue identified potential predictive biomarkers. Among the 42 patients enrolled, the most common toxicities were gastrointestinal and hematologic; dose-limiting toxicities were grade 4 hematologic toxicity and grade 3 fatigue. The once-daily RPh2D was 300 mg. Six patients (14%) had confirmed partial responses: four ovarian, two endometrial. Adavosertib plasma exposures were similar to those from twice-daily dosing. On cycle 1 day 8 (pre-dose), tumor pY15-Cdk levels were higher than baseline in four of eight patients, suggesting target rebound during the day 5 to 8 dosing break. One patient who progressed rapidly had a tumor mutation and potentially compensatory overexpression. Baseline overexpression occurred in both of two responding patients, only one of whom had amplification, and in zero of three nonresponding patients. We determined the once-daily adavosertib RPh2D and observed activity in patients with ovarian or endometrial carcinoma, including two with baseline mRNA overexpression. Future studies will determine whether overexpression is a predictive biomarker for adavosertib.